SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Klippel JH. Systemic lupus erythematosus: treatment-related complications superimposed on chronic disease. JAMA 1990; 263: 18125.
  • 2
    Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 82637.
  • 3
    Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997; 159: 31048.
  • 4
    Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 147080.
  • 5
    Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76: 27585.
  • 6
    Jenkins MK. The ups and downs of T cell costimulation. Immunity 1994; 1: 4436.
  • 7
    Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 11135.
  • 8
    Noelle R, Ledbetter J, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 1992; 13: 4313.
  • 9
    Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994; 15: 40611.
  • 10
    Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, et al. In the absence of a CD40 signal, B cells are tolerogenic. Immunity 1995; 2: 64553.
  • 11
    Mach F, Schonbeck U, Sukhova GK, Bourciev T, Bonnefiy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 1997; 94: 19316.
  • 12
    Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 206373.
  • 13
    Kato K, Santana-Sahagun E, Rassenti L, Weisman MH, Tumura N, Kobayashi S, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104: 94755.
  • 14
    Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996; 14: 591617.
  • 15
    Anderson D, Kloetzer W, Hanna N. Effects of IDEC-131 on induction of inflammatory and procoagulant phenotypes of activated human endothelial cells [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S51.
  • 16
    Anderson D, Pan L-Z, Hanna N. IDEC-131 anti-CD40L monoclonal antibody is a nonagonist of human T lymphocyte activation [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S51.
  • 17
    Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95101.
  • 18
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 19
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 20
    Petri M, Buyon J, Skovron ML. Disease activity and health status (SF-36) in postmenopausal systemic lupus erythematosus: the SELENA trial [abstract]. Arthritis Rheum 1997; 40 Suppl 9: S208.
  • 21
    Symmons DPM, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988; 69: 92737.
  • 22
    Petri M, Buyon J, Skovron ML. Reliability of SELENA SLEDAI and flare as clinical trial outcome measures [abstract]. Arthritis Rheum 1998; 41 (Suppl): S218.
  • 23
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 11213.
  • 24
    Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36: its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 160814.
  • 25
    Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [abstract]. Nat Med 2000; 6: 114.
  • 26
    Mease PJ, Merrill JT, Lahita RG, Petri MA, Ginzler EM, Katz RS, et al. GL701 (Prasterone, dehydroepiandrosterone) improves systemic lupus erythematosus [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S271.